Drug-Induced Interstitial Lung Disease in Lung Cancer Patients
Respiration · 12.11.2025 · 105 (4) · 497-519
DOI: 10.1159/000548862 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Respiration, online erschienen am 12.11.2025. Verfasst von Gilles Vanhandsaeme und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background: Pulmonary toxicity is a possible adverse event (AE) of all systemic treatments for lung cancer. Drug-induced parenchymal and interstitial lung disease (D-ILD) is a rare but potentially life-threatening pulmonary AE. Its clinical and radiological manifestations are highly variable and nonspecific, making recognition and diagnosis particularly challenging. Summary: Effective management of D-ILD requires a high degree of clinical suspicion, supported by education of both patients and healthcare providers. Any lung cancer patient who develops new respiratory symptoms and/or new radiographic abnormalities should be promptly evaluated for possible D-ILD. However, the differential diagnosis is broad, including both infectious and noninfectious etiologies. Clinical, laboratory, microbial, and imaging findings should be incorporated to adjudicate the possibility of D-ILD. Given the absence of a definitive diagnostic test, D-ILD remains a complex diagnosis of exclusion that benefits from a multidisciplinary approach. Pulmonologists play an active role in an integrated diagnostic work-up and management of D-ILD, and they should therefore remain actively engaged in this clinically relevant subject. Key Messages: This review discusses the incidence, risk factors, clinical and radiographic features, and management strategies for D-ILD in the context of current systemic treatments for lung cancer. A practical framework for differential diagnosis is also provided to support clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
- Department of Radiology, University Hospitals Leuven, Leuven, Belgium.
- Laboratory of Experimental Radiotherapy, KU Leuven, Leuven, Belgium.
- Laboratory of Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.
- Center for Cancer Biology, VIB, Leuven, Belgium.
- Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium, els.wauters@uzleuven.be.
Zitieren
APA
Vanhandsaeme, G., Viskens, K., Van Ballaer, V., De Wever, W., Defraene, G., Lambrecht, M., Donders, E., Van Mol, P., & Wauters, E. (2025). Drug-Induced Interstitial Lung Disease in Lung Cancer Patients. Respiration, 105(4), 497-519. https://doi.org/10.1159/000548862
Vancouver
Vanhandsaeme G, Viskens K, Van Ballaer V, De Wever W, Defraene G, Lambrecht M, et al. Drug-Induced Interstitial Lung Disease in Lung Cancer Patients. Respiration. 2025;105(4):497-519. doi:10.1159/000548862
BibTeX
@article{Vanhandsaeme2025,
author = {Vanhandsaeme, Gilles and Viskens, Karolien and Van Ballaer, Valerie and De Wever, Walter and Defraene, Gilles and Lambrecht, Maarten and Donders, Elena and Van Mol, Pierre and Wauters, Els},
title = {Drug-Induced Interstitial Lung Disease in Lung Cancer Patients},
journal = {Respiration},
year = {2025},
volume = {105},
number = {4},
pages = {497--519},
doi = {10.1159/000548862}
}
EUVIMED